AI Insight
Researchers have identified a compound called UNI418 that disrupts DNA repair mechanisms in cancer cells, making them more vulnerable to treatment. When cancer cells develop resistance to therapy, they often do so by becoming better at repairing DNA damage caused by drugs. The study demonstrates that combining UNI418 with PARP inhibitors can restore treatment effectiveness in resistant cancer cells by blocking their ability to fix DNA damage.
Why it matters
This approach offers a potential strategy to overcome one of the biggest challenges in cancer treatment: acquired drug resistance. By targeting DNA repair pathways, this combination therapy could extend the effectiveness of existing cancer treatments and help patients whose cancers have stopped responding to standard therapies.
Cancer cells often survive treatment by fixing the DNA damage that therapy is meant to cause. Researchers found that UNI418 can disrupt this repair ability, leaving cancer cells more exposed. When combined with a PARP inhibitor, it helped resistant cancer cells respond to treatment again. The findings point to a new strategy for overcoming cancer drug resistance.
Source: Scientists shut down cancer DNA repair to overcome drug resistance